-
Je něco špatně v tomto záznamu ?
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases
C. Le Terrier, P. Mlynarcik, M. Sadek, P. Nordmann, L. Poirel
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
Université de Fribourg (Universität Freiburg)
National Institute of Virology and Bacteriology (Programme EXCELES, ID Project No. LX22NPO5103) - funded by the European Union - Next Generation EU
NLK
Free Medical Journals
od 1972 do Před 6 měsíci
Freely Accessible Science Journals
od 1995 do Před 6 měsíci
PubMed Central
od 1972 do Před 1 rokem
Europe PubMed Central
od 1972 do Před 6 měsíci
Open Access Digital Library
od 1972-01-01
Open Access Digital Library
od 1972-01-01
PubMed
39365068
DOI
10.1128/aac.00775-24
Knihovny.cz E-zdroje
- MeSH
- Acinetobacter baumannii * účinky léků enzymologie MeSH
- antibakteriální látky * farmakologie chemie MeSH
- azabicyklické sloučeniny * farmakologie chemie MeSH
- bakteriální proteiny * antagonisté a inhibitory metabolismus MeSH
- beta-laktamasy * metabolismus MeSH
- bicyklické sloučeniny heterocyklické farmakologie chemie MeSH
- cyklooktany MeSH
- inhibitory beta-laktamasy * farmakologie chemie MeSH
- kyseliny boronové * farmakologie chemie MeSH
- laktamy MeSH
- mikrobiální testy citlivosti * MeSH
- peniciliny farmakologie chemie MeSH
- piperidiny MeSH
- sulfony farmakologie chemie MeSH
- Publikační typ
- časopisecké články MeSH
The relative inhibitory activities of diazabicyclooctanes (avibactam, relebactam, zidebactam, nacubactam, durlobactam), boronic acid derivatives (vaborbactam, taniborbactam, xeruborbactam), and penicillin-based sulfone derivative enmetazobactam were evaluated against several intrinsic and acquired class C β-lactamases. By contrast to vaborbactam and enmetazobactam, taniborbactam, xeruborbactam, and all diazabicyclooctanes demonstrated effective activities against most AmpC enzymes. Notably, durlobactam exhibited the most pronounced inhibitory effect. Interstingly, the chromosomal AmpC of Acinetobacter baumannii was the least sensitive enzyme to the newly developed β-lactamase inhibitors.
Division of Intensive Care Unit University Hospitals of Geneva Geneva Switzerland
Swiss National Reference Center for Emerging Antibiotic Resistance Fribourg Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003511
- 003
- CZ-PrNML
- 005
- 20250206104402.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1128/aac.00775-24 $2 doi
- 035 __
- $a (PubMed)39365068
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Le Terrier, Christophe $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland $1 https://orcid.org/0000000254555576
- 245 10
- $a Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases / $c C. Le Terrier, P. Mlynarcik, M. Sadek, P. Nordmann, L. Poirel
- 520 9_
- $a The relative inhibitory activities of diazabicyclooctanes (avibactam, relebactam, zidebactam, nacubactam, durlobactam), boronic acid derivatives (vaborbactam, taniborbactam, xeruborbactam), and penicillin-based sulfone derivative enmetazobactam were evaluated against several intrinsic and acquired class C β-lactamases. By contrast to vaborbactam and enmetazobactam, taniborbactam, xeruborbactam, and all diazabicyclooctanes demonstrated effective activities against most AmpC enzymes. Notably, durlobactam exhibited the most pronounced inhibitory effect. Interstingly, the chromosomal AmpC of Acinetobacter baumannii was the least sensitive enzyme to the newly developed β-lactamase inhibitors.
- 650 12
- $a azabicyklické sloučeniny $x farmakologie $x chemie $7 D053961
- 650 12
- $a inhibitory beta-laktamasy $x farmakologie $x chemie $7 D065093
- 650 12
- $a kyseliny boronové $x farmakologie $x chemie $7 D001897
- 650 12
- $a beta-laktamasy $x metabolismus $7 D001618
- 650 12
- $a mikrobiální testy citlivosti $7 D008826
- 650 12
- $a Acinetobacter baumannii $x účinky léků $x enzymologie $7 D040981
- 650 12
- $a antibakteriální látky $x farmakologie $x chemie $7 D000900
- 650 12
- $a bakteriální proteiny $x antagonisté a inhibitory $x metabolismus $7 D001426
- 650 _2
- $a peniciliny $x farmakologie $x chemie $7 D010406
- 650 _2
- $a sulfony $x farmakologie $x chemie $7 D013450
- 650 _2
- $a bicyklické sloučeniny heterocyklické $x farmakologie $x chemie $7 D019086
- 650 _2
- $a laktamy $7 D007769
- 650 _2
- $a piperidiny $7 D010880
- 650 _2
- $a cyklooktany $7 D034242
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mlynarcik, Patrik $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czechia $1 https://orcid.org/000000031496775X
- 700 1_
- $a Sadek, Mustafa $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt $1 https://orcid.org/0000000339833862
- 700 1_
- $a Nordmann, Patrice $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland $1 https://orcid.org/0000000213431622
- 700 1_
- $a Poirel, Laurent $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland $1 https://orcid.org/0000000151605286
- 773 0_
- $w MED00009215 $t Antimicrobial agents and chemotherapy $x 1098-6596 $g Roč. 68, č. 11 (2024), s. e0077524
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39365068 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104358 $b ABA008
- 999 __
- $a ok $b bmc $g 2263335 $s 1239518
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 68 $c 11 $d e0077524 $e 20241004 $i 1098-6596 $m Antimicrobial agents and chemotherapy $n Antimicrob Agents Chemother $x MED00009215
- GRA __
- $p Université de Fribourg (Universität Freiburg)
- GRA __
- $p National Institute of Virology and Bacteriology (Programme EXCELES, ID Project No. LX22NPO5103) - funded by the European Union - Next Generation EU
- LZP __
- $a Pubmed-20250121
